Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer

Journal of Clinical Oncology

Volumn 21, Issue 5, 2003, Pages 884-890

  Chang, Alfred E ^a   Li, Qiao ^a   Jiang, Guihua ^a   Sayre, Donna M ^a   Braun, Thomas M ^a   Redman, Bruce G ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; CANCER VACCINE; CD3 ANTIGEN; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNIZATION; CANCER STAGING; CELL ACTIVATION; CELL THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; LYMPH NODE; LYMPHOCYTE; LYMPHOID CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR CELL CULTURE; TUMOR REGRESSION; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; CELLULAR IMMUNITY; DRUG EFFECT; FEMALE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUMOR; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MYCOBACTERIUM BOVIS; PHENOTYPE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION;

ADOPTIVE TRANSFER; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CANCER VACCINES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; INFUSIONS, INTRAVENOUS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; NEOPLASM STAGING; PHENOTYPE; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINATION;

EID: 0037365973     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.023     Document Type: Article

References (34)

1. Rosenberg SA, Spiess P, Lafreniere P: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321, 1986
2. Chou T, Bertera S, Chang AE, et al: Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol 141:1775-1781, 1988
3. Hewitt HB, Blake ER, Walder AS: A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 33:241-259, 1976
4. Hewitt HB: Second point: Animal tumor models and their relevance to human tumor immunology. J Biol Response Mod 2:210-216, 1983
5. Sakai K, Chang AE, Shu S: Effector phenotype and immunologic specificity of T cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity. Cell Immunol 129:241-255, 1990
6. Geiger JD, Wagner PD, Shu S, et al: A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg Oncol 1:199-208, 1992
7. Geiger JD, Wagner PD, Cameron MJ, et al: Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother 13:153-165, 1993
8. Stephenson KR, Perry-Lalley D, Griffith KD, et al: Development of antitumor reactivity in regional draining lymph nodes from tumor-immunized and tumor-bearing murine hosts. Surgery 105:523-528, 1989
9. Yoshizawa H, Chang AE Shu S: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147:729-737, 1991
10. Chang AE, Aruga A, Cameron MJ, et al: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15:796-807, 1997
11. Li Q, Zeng X, Sun R, et al: Immunological effects of BCG as an adjuvant in autologous tumor vaccines. Clin Immunol 94:64-72, 2000
12. Chang AE, Li Q, Jiang G, et al: Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer. Head and Neck (in press)
13. Chang AE, Yoshizawa H, Sakai K, et al: Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 53:1043-1050, 1993
14. Rosenberg SA, Lotze M, Yang J, et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-484, 1989
15. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus IL-2. JAMA 271:907-913, 1994
16. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995
17. Aruga A, Aruga E, Cameron MJ, et al: Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. J Leukoc Biol 61:1-10, 1997
18. Curti BD, Longo DL, Ochoa AC, et al: Treatment of cancer patients with ex vivo anti-CD3 activated killer cells and interleukin-2. J Clin Oncol 11:652-660, 1993
19. Curti BD, Ochoa AC, Urba WJ, et al: Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: Results from a phase I trial in cancer patients. J Immunother 19:296-308, 1996
20. Aruga A, Aruga E, Tanigawa K, et al: Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 159:664-673, 1997
21. Li Q, Yu B, Grover AC, et al: Preferential activation of tumor reactive CD4+ cells from tumor-primed lymph nodes with anti-CD3/anti-CD28 monoclonal antibodies. J Immunother 25:304-313, 2002
22. + T-cell responses to human cancers induced by secondary anti-CD3/ anti-CD28 activation. Clin Cancer Res 5:461-469, 1999
23. Yoshizawa H, Chang AE, Shu S: Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res 52:1129-1136, 1992
24. Curti BD, Ochoa AC, Powers GC, et al: Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2 and cyclophosphamide in patients with advanced cancer. J Clin Oncol 16:2752-2760, 1998
25. Vinay DS, Kwon BS: Role of 4-1BB in immune responses. Semin Immunol 10:481-489, 1998
26. Hurtado JC, Kim YJ, Kwon BS: Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 158:2600-2609, 1997
27. Wilcox RA, Chapoval AI, Gorski KS, et al: Expression of functional CD137 receptor by dendritic cells. J Immunol 168:4262-4267, 2002
28. Li Q, Yu B, Grover A, et al: Synergistic effects of 4-1BB and CD28 co-stimulation in up-regulating type 1 vs. type 2 cytokine secretion of tumor reactive T-cells. Proc Am Assoc Cancer Res 42:844, 2001 (abstr)
29. Li Q, Ito F, Carr A, et al: Adoptive immunotherapy of murine tumor MCA205 using tumor-reactive T cells generated through 4-1BB and CD28 co-stimulation. Proc Am Assoc Cancer Res 43:255, 2002 (abstr)
30. Tanigawa K, Takeshita N, Craig R, et al: Tumor-specific responses in lymph nodes draining murine sarcomas are concentrated in cells expressing P-selectin binding sites. J Immunol 167:3089-3098, 2001
31. Tietz WY, Allemand E, Borges D, et al: CD4+ T cells migrate into inflamed skin only if they express ligands for E- and P-selectin. J Immunol 161:963-970, 1998
32. Xie H, Lim YC, Luscinskas FW, et al: Acquisition of selectin binding and peripheral homing properties by CD4(+) and CD8(+) T cells. J Exp Med 189:1765-1776, 1999
33. Wagers AJ, Waters CM, Stoolman LM: Interleukin 12 and interleukin 4 control T cell adhesion to endothelial selectins through opposite effects on alpha1, 3-fucosyltransferase VII gene expression. J Exp Med 188:2225-2231, 1998
34. Austrup F, Vestweber D, Borges E, et al: P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature 385:81-83, 1997